Nobelpharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nobelpharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7585
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company that develops medicines for rare diseases and unmet medical needs. The company’s pipeline products include NPC-09, NPC-12, NPC-15, NPC-16, NPC-17 and NPC-18. It offers products in the therapeutic areas of oncology, metabolic diseases; neurology, genetic disorders, women’s health and respiratory. NobelPharma conducts research and development of drugs under categories such as orphan drugs, off-label drug, medicines used for additional efficacy, and pediatric pharmaceuticals. The company operates its branch offices in Hokkaido-Tohoku, Kanshinetu, Tokyo, Minamikanto, Tokai-Hokuriku, Kansai, Chu-Shikoku, and Kyushu, Japan. NobelPharma is headquartered in Tokyo, Japan.

Nobelpharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
NobelPharma Enters into Agreement with TOKUHON 11
Licensing Agreements 12
NobelPharma Enters into Licensing Agreement with Osaka University 12
NobelPharma Enters into Licensing Agreement with Kitasato University 13
NobelPharma Enters into Licensing Agreement with Savara 14
NobelPharma Enters into Licensing Agreement with Kurume University 15
NobelPharma Enters into Licensing Agreement with Serendex Pharma 16
NobelPharma Enters into Licensing Agreement with Gifu University 17
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 18
SRI International Enters into Licensing Agreement with Nobelpharma 19
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 20
Nobelpharma Co Ltd – Key Competitors 21
Nobelpharma Co Ltd – Key Employees 22
Nobelpharma Co Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nobelpharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
NobelPharma Enters into Agreement with TOKUHON 11
NobelPharma Enters into Licensing Agreement with Osaka University 12
NobelPharma Enters into Licensing Agreement with Kitasato University 13
NobelPharma Enters into Licensing Agreement with Savara 14
NobelPharma Enters into Licensing Agreement with Kurume University 15
NobelPharma Enters into Licensing Agreement with Serendex Pharma 16
NobelPharma Enters into Licensing Agreement with Gifu University 17
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 18
SRI International Enters into Licensing Agreement with Nobelpharma 19
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 20
Nobelpharma Co Ltd, Key Competitors 21
Nobelpharma Co Ltd, Key Employees 22
Nobelpharma Co Ltd, Other Locations 24

List of Figures
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Nobelpharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ABN AMRO Group NV (ABN):企業の財務・戦略的SWOT分析
    ABN AMRO Group NV (ABN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Genuine Parts Company (GPC):企業の財務・戦略的SWOT分析
    Genuine Parts Company (GPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • BioStar Pharmaceuticals Inc (BSPM):企業の財務・戦略的SWOT分析
    Summary BioStar Pharmaceuticals Inc (BioStar) is a developer, manufacturer and marketer of pharmaceutical and healthcare supplement products for various diseases and conditions. The company offers products such as huangyangning tablets, hyperthyroidism capsules, danshen granule, aoxing oleanolic aci …
  • Sensus USA Inc.-エネルギー分野:企業M&A・提携分析
    Summary Sensus USA Inc. (Sensus), a Xylem brand, is a clean technology solutions company that designs and manufactures smart meters, communication systems, and software. It provides smart meters, network technologies, and advanced data analytics solutions. Sensus’s solutions collects data related to …
  • CROS NT srl-製薬・医療分野:企業M&A・提携分析
    Summary CROS NT srl (CROS NT) is a contract research organization (CRO), which specializes in clinical data management, analysis, reporting and technologies. Its services include programming, analysis, medical writing, CROS academy training, methodology and clinical data management. Its outsourcing …
  • Digi International, Inc. (DGII):企業の財務・戦略的SWOT分析
    Digi International, Inc. (DGII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Ultradent Products Inc:企業の戦略的SWOT分析
    Ultradent Products Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cellnovo Ltd-医療機器分野:企業M&A・提携分析
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management system, including an insulin patch pump, activity monitor, cellular-enabled wireless touchscreen handset with integrated bl …
  • Deere & Company:企業の戦略・SWOT・財務情報
    Deere & Company - Strategy, SWOT and Corporate Finance Report Summary Deere & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • FANUC CORPORATION:企業の戦略・SWOT・財務情報
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tizona Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tizona Therapeutics Inc (Tizona Therapeutics) is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading …
  • Sientra Inc (SIEN):企業の財務・戦略的SWOT分析
    Summary Sientra Inc (Sientra) is a medical device company that manufactures and markets plastic surgery implantable devices. The company’s products comprise breast implants, breast tissue expanders, silicone scar treatment and additional tissue expanders. It offers reconstructive surgery devices suc …
  • Culp Inc (CULP):企業の財務・戦略的SWOT分析
    Culp Inc (CULP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Wentworth Resources Ltd (WRL)-石油・ガス分野:企業M&A・提携分析
    Summary Wentworth Resources Limited (Wentworth) is an independent upstream oil and gas company. It conducts the exploration and development of oil and natural gas reserves. The company has producing gas assets in Tanzania, oil and gas exploration activities in both Mozambique and Tanzania. The compa …
  • Asseco Business Solutions SA (ABS):企業の財務・戦略的SWOT分析
    Asseco Business Solutions SA (ABS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • OpenWay Group:企業の戦略的SWOT分析
    OpenWay Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Almac Discovery Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Almac Discovery Ltd (Almac Discovery) a subsidiary of Almac Group Ltd is a healthcare service provider that discovers and develops drugs for the treatment of cancer. The company develops drugs, small molecule and therapeutic peptide, biomarkers and diagnostic tools. It provides early drug di …
  • AirStrip Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary AirStrip Technologies Inc (AirStrip) is a healthcare solution provider that offers medical software solutions and services. The company offers mobile interoperability platform interoperability platform that offers access to critical patient data and intelligent insights across the care conti …
  • Ocwen Financial Corporation:企業のM&A・事業提携・投資動向
    Ocwen Financial Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ocwen Financial Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Cheniere Energy Inc (LNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Cheniere Energy Inc (Cheniere) is a midstream energy company that owns and operates LNG-related businesses. The company through its general partner, Cheniere Energy Partners, L.P. (Cheniere Partners) and Cheniere Energy Partners LP Holdings (Cheniere Holdings) owns and operates the Sabine Pa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆